Most Recent
The Full Federal Court has tossed an appeal by Johnson & Johnson unit Ethicon challenging a landmark decision that put it on the hook for paying damages to 10,000 women who suffered injury through defects in its prolapse mesh and incontinence tape implants.
Pelvic mesh device maker Astora Women's Health is weighing whether to make admissions in a class action over allegedly defective products in light of a similar, high profile class action brought against Johnson & Johnson unit Ethicon over the devices.
A group of women harmed by pelvic mesh devices produced by Johnson & Johnson have accused it of persisting with a "wreckage" of a case in which one of its own doctors admitted the pharmaceutical company knew of the risks posed by the implants at they time they were sold worldwide.
The judge who found J&J's pelvic mesh implants defective in a high stakes class action ruling mde a "pervasive error" in disregarding the knowledge and views of the applicants' doctors, an appeals court has heard.
A unit of Johnson & Johnson has been ordered to pay around $40 million in legal costs to the lead applicants in a class action over pelvic mesh implants after a judge dismissed the company's bid to stay the costs until after a high profile appeal is heard next year.
A judge due to hear a high profile appeal by Johnson & Johnson unit Ethicon has expressed confusion about the grounds on which the medical device maker is challenging a landmark judgment putting it on the hook for potentially hundreds of million of dollars in damages over faulty pelvic mesh implants.
Drug manufacturer Janssen wants to expand its high stakes case against Juno Pharmaceuticals over its HIV drug Prezista, alleging Juno's plans to launch a generic version of the drug threaten another one of its patents.
Drug maker Janssen has fired off a lawsuit against Juno Pharmaceuticals for allegedly threatening to infringe a patent for its HIV drug Prezista with a generic version of the drug, one year after fending off generic competition from a different drug maker.
Medical device giant Johnson & Johnson has confirmed it will not seek the recusal of a Federal Court judge from a panel overseeing its pelvic mesh class action appeal, despite earlier raising concerns that he had seen privileged settlement communications.
The top judge of the Federal Court plans to clear the schedules of three judges at the start of next year so they can hear and decide Johnson & Johnson's challenge of a class action ruling that found its pelvic mesh devices were defective and awarded the lead applicants $2.6 million in damages.